Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
Trial details
- Registry ID
- NCT06247085
- Drugs studied
- Pegtibatinase
TrialRedline tracks 7 clinical trials sponsored by Travere Therapeutics, Inc.: 4 Phase 3, 3 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentNCT06247085 | Pegtibatinase | Recruiting | 2027-08Estimated |
| A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)NCT06431893 | Pegtibatinase | Enrolling by invitation | 2030-08Estimated |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850 | Dapagliflozin, irbesartan, sparsentan | Completed | 2023-08-07Actual |
| Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)NCT03493685 | Irbesartan, sparsentan | Completed | 2023-03-20Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesNCT05003986 | Sparsentan | Recruiting | 2027-03-12Estimated |
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANNCT05856760 | Sparsentan | Completed | 2024-10-14Actual |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental GlomerulosclerosisNCT01613118 | Irbesartan, RE-021 (Sparsentan) | Completed | 2016-06Actual |
Names as written in the registry records.
NCT03762850 · Travere Therapeutics, Inc.
Before: Active not recruiting. After: Completed.
Before: Jan 2027. After: Aug 2030.
NCT06247085 · Travere Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in plasma tHcy levels. After: Measure: Change from baseline in plasma tHcy levels - Weeks 6 to 12.
Before: Dec 2025. After: Aug 2027.
Before: Active not recruiting. After: Recruiting.
NCT03493685 · Travere Therapeutics, Inc.
Before: Active not recruiting. After: Completed.